Kastenhuber Edward R, Craig John, Ramsey Jon, Sullivan Kevin M, Sage Julien, de Oliveira Sofia, Riehle Kimberly J, Scott John D, Gordan John D, Bardeesy Nabeel, Abou-Alfa Ghassan K
Cancer Biology and Genetics Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA,
Louis V. Gerstner Jr. Graduate School of Biomedical Sciences, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
J Hepatocell Carcinoma. 2019 Jan 31;6:41-48. doi: 10.2147/JHC.S194764. eCollection 2019.
Fibrolamellar carcinoma is a rare liver cancer, which primarily afflicts adolescents and young adults worldwide and is frequently lethal. Given the rarity of this disease, patient recruitment for clinical trials remains a challenge. In November 2017, the Second Fibrolamellar Cancer Foundation Scientific Summit (Stamford, CT, USA) provided an opportunity for investigators to discuss recent advances in the characterization of the disease and its surrounding liver and immune context. The Fibrolamellar Cancer Foundation has thus set out a road map to identify and test therapeutic targets in the most efficient possible manner.
纤维板层癌是一种罕见的肝癌，主要困扰全球的青少年和年轻成年人，且往往具有致命性。鉴于这种疾病的罕见性，招募患者进行临床试验仍然是一项挑战。2017年11月，第二届纤维板层癌基金会科学峰会（美国康涅狄格州斯坦福德）为研究人员提供了一个机会，以讨论该疾病及其周围肝脏和免疫环境特征的最新进展。纤维板层癌基金会因此制定了一个路线图，以尽可能高效的方式识别和测试治疗靶点。
